Abstract: Nanoparticles comprising VIP and their use in treating, e.g., pulmonary hypertension. Such nanoparticles provide improved delivery of VIP and allow for acute treatment and optionally for sustained release of VIP in a patient.
Type:
Application
Filed:
June 15, 2016
Publication date:
February 23, 2017
Applicant:
AVANT GARDE THERAPEUTICS AND TECHNOLOGIES, LLC
Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
Type:
Grant
Filed:
February 26, 2013
Date of Patent:
July 5, 2016
Assignee:
AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC
Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
Type:
Application
Filed:
February 26, 2013
Publication date:
September 19, 2013
Applicant:
Avant Garde Therapeutics and Technologies LLC
Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
Type:
Grant
Filed:
June 8, 2010
Date of Patent:
March 26, 2013
Assignee:
Avant Garde Therapeutics & Technologies LLC
Abstract: A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest, bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity, or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can be delivered. A method for the treatment of cardiac arrest or pulmonary hypertension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
May 22, 2012
Assignee:
Avant Garde Therapeutics & Technologies LLC